VJHemOnc is committed to improving our service to you

SOHO 2020 | Targeting BCL-2 in MDS

VJHemOnc is committed to improving our service to you

Amer Zeidan

Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, discusses agents targeting BCL-2 in the treatment of myelodysplastic syndromes (MDS), including luspatercept as well as an orally available version of decitabine. Dr Zeidan also highlights novel agents investigated in Phase I and II trials, including venetoclax in combination with azacitidine, which targets anti-apoptotic signals within cancer cells and shows promising activity in relapsed/refractory patients with MDS. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter